Details of the Drug

General Information of Drug (ID: DMCS6M5)

Drug Name

Voxelotor

Synonyms

Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Approved	[1]

ATC Code

B06AX03: Voxelotor

B06AX: Other hematological agents

B06A: OTHER HEMATOLOGICAL AGENTS

B06: OTHER HEMATOLOGICAL AGENTS

B: BLOOD AND BLOOD FORMING ORGANS

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

337.4

Logarithm of the Partition Coefficient (xlogp)

2.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
Clearance: The apparent oral clearance of drug is 6.7 L/h [3]
Elimination: 62.6% of the voxelotor dose administered orally as well as its metabolites are found in the feces (with 33.3% as unchanged drug) and 35.5% in urine (with only 0.08% unchanged drug) [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 35.5 hours [3]
Vd: The volume of distribution (Vd) of drug is 338 L [3]

Chemical Identifiers

Formula: C19H19N3O3
IUPAC Name: 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
Canonical SMILES: CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
InChI: InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
InChIKey: FWCVZAQENIZVMY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71602803
ChEBI ID: CHEMBL4101807
CAS Number: 1446321-46-5
UNII: 3ZO554A4Q8
DrugBank ID: DB14975
TTD ID: D09RII
INTEDE ID: DR1713
ACDINA ID: D01530

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Modulator	[1]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[4]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[4]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[4]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Voxelotor (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Avapritinib	DMK2GZX	Major	Decreased metabolism of Voxelotor caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[5]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Voxelotor caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[6]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Voxelotor caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[7]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Voxelotor caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[8]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Voxelotor caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[9]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Voxelotor caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[10]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Voxelotor caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[11]


⏷ Show the Full List of 7 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Colcothar yellow	E00436	518696	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Voxelotor 500 mg tablet	500 mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	Hutchaleelaha A, Patel M, Washington C, Siu V, Allen E, Oksenberg D, Gretler DD, Mant T, Lehrer-Graiwer J: Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. Br J Clin Pharmacol. 2019 Jun;85(6):1290-1302. doi: 10.1111/bcp.13896. Epub 2019 Mar 31.
3	FDA Approved Drug Products: Oxbryta (voxelotor) tablets
4	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
5	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
7	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
8	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
9	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
10	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
11	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.